Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 13/20 | 0.61 |
| ▸ | LTB4R2 | Q9NPC1 | 9/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683543 | 0.92 | AGTR1 (0.64) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL29669823 | 0.91 | AGTR1 (0.73) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2252 | 0.91 | AGTR1 (0.73) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2373 | 0.91 | AGTR1 (0.73) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2251 | 0.91 | AGTR1 (0.73) | AGTR1LTB4R2ABCB11GP6 | |
| Acetic Acid SCHEMBL28371506 | 0.89 | AGTR1 (0.62) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL4473044 | 0.89 | AGTR1 (0.64) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2950 | 0.89 | AGTR1 (0.61) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2691 | 0.89 | AGTR1 (0.61) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL14193717 | 0.89 | AGTR1 (0.61) | AGTR1LTB4R2ABCB11GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249429-A1 | PROCESS FOR THE MANUFACTURE OF VALSARTAN | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-20100249429-A1 | PROCESS FOR THE MANUFACTURE OF VALSARTAN | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-20090111995-A1 | Process for the manufacture valsartan | NOVARTIS AG (CH) | 2009-04-30 | — | — | US | disclosed |
| US-20090111995-A1 | Process for the manufacture valsartan | NOVARTIS AG (CH) | 2009-04-30 | — | — | US | disclosed |
| EP-1878729-A1 | INTERMEDIATE FOR THE MANUFACTURE OF VALSARTAN | Novartis AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| WO-2004026847-A1 | PROCESS FOR THE MANUFACTURE OF VALSARTAN | NOVARTIS AG (CH) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249429-A1 | PROCESS FOR THE MANUFACTURE OF VALSARTAN | AGTR1, AGTR2, AGT | AGTR1 1/4885LTB4R2 674/4885ABCB11 999/4885 |
| US-20090111995-A1 | Process for the manufacture valsartan | AGTR1, AGTR2, AGT | AGTR1 1/4885LTB4R2 750/4885ABCB11 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.